- Home
- ANL vs CUE Comparison
ANL vs CUE Comparison
Compare ANL & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANL | CUE |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.9M | 27.1M |
| IPO Year | 2022 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ANL | CUE |
|---|---|---|
| Price | $9.07 | $0.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $16.00 | $3.00 |
| AVG Volume (30 Days) | 218.7K | ★ 316.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 35.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,287,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 69.16 |
| 52 Week Low | $0.88 | $0.23 |
| 52 Week High | $12.09 | $1.12 |
Technical Indicators
Market Signals| Indicator | ANL | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 57.38 | 47.64 |
| Support Level | $1.37 | $0.29 |
| Resistance Level | $10.15 | $0.36 |
| Average True Range (ATR) | 0.92 | 0.02 |
| MACD | -0.32 | 0.00 |
| Stochastic Oscillator | 60.88 | 73.35 |
Price Performance
Historical ComparisonAbout ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.